ABC-X : A phase II, open-label, randomised, controlled trial of Ipilimumab and Nivolumab with concurrent intracranial stereotactic radiotherapy versus Ipilimumab and Nivolumab alone in patients with melanoma brain metastases

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Radiotherapy<br/>TrialTypeRadiotherapy
Trial

TwoPhase Two

18+Age Over 18

Brain and Spinal<br/>CancersCancer LocationBrain and Spinal
Cancers

Radiotherapy,Systemic therapy | Brain and spinal cordBrain

Trial Overview Read MoreRead more

This phase II trial is evaluating the effectiveness of using two targeted therapies (ipilimumab and nivolumab) in combination with intracranial stereotactic radiotherapy to treat melanoma brain metastases.
 

This trial is treating patients with Melanoma Brain Metastases.

This is a systemic therapy and radiotherapy trial.

You may be able to join this trial if:

  • You have had a certain type of treatment or surgical procedure.
  • You have had treatment, but your cancer has come back.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A phase II, open-label, randomised, controlled trial of Ipilimumab and Nivolumab with concurrent intracranial stereotactic radiotherapy versus Ipilimumab and Nivolumab alone in patients with melanoma brain metastases

Commercial Sponsor

Bristol-Myers Squibb (BMS)

Other Non-Commercial Sponsor

Melanoma Institute Australia

Summary

All eligible patients will receive Nivolumab and Ipilimumab every three weeks for four cycles, then Nivolumab every 4 weeks. Some patients will receive either a single or multiple sessions of stereotactic radiotherapy, within the first 5 days of the targeted therapy. Salvage therapy may be administered to any patient if the disease progresses.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Enquiries Line Coordinator
clinicaltrials.enquiries@petermac.org
03 8559 7456 (9am-2pm, Mon-Fri)

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next